Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;4(1):32-8.
Epub 2014 Apr 20.

Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia

F Azimi  1 , M Jafariyan  1 , S Khatami  2 , Y Mortazavi  3 , M Azad  4
Affiliations
Review

Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia

F Azimi et al. Iran J Ped Hematol Oncol. 2014.

Abstract

For the past half century, thiopurines have earned themselves a reputation as effective anti-cancer and immunosuppressive drugs. Thiopurine S-methyltransferase (TPMT) is involved in the metabolism of all thiopurines and is one of the main enzymes that inactivates mercaptopurine. 6-MP is now used as a combination therapies for maintenance therapy of children with acute lymphocytic leukemia (ALL). In all patients receiving mercaptopurine, there is a risk of bone marrow suppression. TPMT activity is inherited as a monogenic, co-dominant trait. More than 25 variants are known. Genetic testing is available for several TPMT variant alleles. Most commonly TPMT*2, *3A, and *3C are tested for, which account for >90% of inactivating alleles. Differences in DNA that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals.Genotyping may become part of routine investigations to help clinicians tailor drug treatment effectively. This success is mainly due to the development of combination therapies and stratification of patients according to risk of treatment failure and relapse, rather than the discovery of new drugs. The aim of this study was to investigate the effect of genotype or methyltransferase enzyme activity before starting therapy in children with ALL. This can prevent the side effect of thiopurine drugs. In fact, the common polymorphism of this enzyme in population could be a prognostic factor in relation to drug use and treatment of patients with ALL.

Keywords: 6-Mercaptopurine; 6-Thioguanine; Acute lymphoblastic leukemia; Azathioprine; Myelosuppression; Polymorphism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The metabolism of 6-mercaptopurine
See this image and copyright information in PMC

References

    1. Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, et al. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 1995;13(10):2490–6. - PubMed
    1. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet. 1989;16(6):327–36. - PubMed
    1. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11(2):177–88. - PubMed
    1. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts therapylimiting severe toxicity from azathioprine. Ann Intern. Med. . 1998;129:716–18. - PubMed
    1. Lennard, L, Lilleyman, J.S, Van Loon, J, Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225–29. - PubMed

LinkOut - more resources